Evotec AG (Germany), a drug discovery alliance and development partnership company, and Almirall S.A. (Spain), a leading skin-health focused global pharmaceutical company, announced that they have entered into a research collaboration.
The collaboration is intended to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signalling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis.
The cooperation combines Evotec’s cutting-edge drug discovery and pre-clinical development platforms with Almirall’s leading expertise in dermatology diseases. Under the terms of the agreement, Evotec will receive research funding and may be eligible to receive discovery, pre-clinical, clinical and sales milestone payments as well as tiered royalties.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented:
“Evotec is pleased to partner with Almirall in the field of dermatology, who is a globally recognised leader in the field. The goal is to jointly address highly validated targets via a new approach that has the potential to deliver superior first-in-class drug products. This platform enables disruption of cell signalling via a new approach that has been identified and developed by Evotec scientists in Toulouse and is expected to deliver many more drug discovery opportunities.”
Founded in 1943 and headquartered in Barcelona (Spain), Almirall is a consolidated international pharmaceutical company. The company has three R&D centres distributed in Spain and Germany (Reinbek) and Switzerland (Lugano). The R&D centre in Sant Feliu de Llobregat (Barcelona), houses the departments involved in all stages of R&D, as well as the development of new chemical entities. The Reinbek Centre of Excellence for Dermatology specializes in the development of new formulas for the treatment of skin diseases.